Table 4 Comparisons of Clinical characteristics between quinolone-susceptible and quinolone-resistant groups

Age, years

63.0 (51.0–70.0)

66.0 (53.5–72.5)

0.215

Age ≥ 65 years, n(%)

37 (43.0)

20 (51.3)

0.390

Gender, male

57 (66.3)

29 (64.6)

0.233

 HTN

30 (34.9)

16 (41.0)

0.509

 DM

29 (33.7)

10 (25.6)

0.366

 Cardiovascular disease

13 (15.1)

9 (23.1)

0.279

 Chronic kidney disease

6 (7.0)

2 (5.1)

1.000

 End stage renal disease

4 (4.7)

4 (10.3)

0.255

 Chronic liver disease

12 (14.0)

4 (10.3)

0.774

 Pulmonary disease

8 (9.3)

4 (10.3)

1.000

 Solid tumor

42 (48.8)

19 (48.7)

0.990

 Hematologic malignancy

12 (14.0)

6 (15.4)

0.833

 Solid organ transplantation

5 (5.8)

2 (5.1)

1.000

 Charlson score

6.1 ± 3.1

7.4 ± 3.2

0.030

 Chemotherapy

11 (12.8)

3 (7.7)

0.546

 Major surgery^a

28 (32.9)

16 (35.4)

0.382

 ICU care

54 (62.8)

29 (74.4)

0.205

 Hospital stay before bacteremia, days

17.0 (8.0–34.0)

30.0 (13.5–57.5)

0.015

 Central venous catheter

57 (66.3)

32 (84.2)

0.019

 Hemodialysis catheter

9 (10.5)

8 (21.6)

0.100

 Mechanical ventilator

36 (41.9)

24 (63.2)

0.029

 Foley catheter

47 (54.7)

28 (73.7)

0.046

 Shock

23 (26.7)

20 (51.3)

0.007

 APACHE II score

13.0 (8.0; 18.0)

14.0 (11.0; 21.5)

0.115

 Neutropenia

14 (16.3)

4 (10.3)

0.374

 Hypoalbuminemia

52 (60.5)

21 (53.8)

0.487

 Thrombocytopenia

28 (32.6)

19 (48.7)

0.084

 Hemoglobin, g/L

9.8 ± 1.7

9.4 ± 1.3

0.296

 C-reactive protein, mg/L

86.8 (41.5–142.5)

79.3 (44.5–153.0)

0.914

 Estimated GFR, ml/min per 1.73m²

87.0 (51.0–101.0)

72.0 (45.4–106.0)

0.592

 Inappropriate antimicrobial therapy

23 (26.7)

16 (42.1)

0.089

 Hospital stay, days

50.0 (26.0–78.0)

68.0 (35.0–150.0)

0.054

 Mortality

48 (55.8)

34 (87.2)

0.001